The successful use of gene therapy to correct rare immune system disorders has highlighted the enormous potential of such therapies. We review the current state of gene therapy for childhood immune system disorders, and consider why these conditions have been particularly amenable to genetic correction. As with all emerging therapies, there have been unexpected side effects and their underlying mechanisms are the subject of intense research. Minimising such risks through improved vector design will play an important role in developing the next generation of gene based therapies and extending their applicability.
- gene therapy
- retroviral vectors
- severe combined immunodeficiency
Statistics from Altmetric.com
Waseem Qasim is supported by the Leukaemia Research Fund and Adrian Thrasher is a Senior Wellcome Trust fellow.
Competing interests: None.
- adenosine deaminase
- chronic granulomatous disease
- haematopoietic stem cell transplantation
- long terminal repeat
- severe combined immune deficiency
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.